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BACKGROUND
While rates of death due to cardiovascular diseases have declined over the past decades in both the United States and Europe, the attributable burden remains high.
1, 2 Among these, acute coronary syndromes (ACS) represent the most frequent conditions in clinical practice.
The spectrum comprises, based on electrocardiographic criteria and troponin elevation values, ST-segment elevation myocardial infarction (STEMI), non-ST-segment myocardial infarction (NSTEMI), and unstable angina (UA). 3 Percutaneous coronary intervention (PCI) has been established as standard for revascularization in these patients, as the procedure relieves symptoms, shortens hospital stays, and improves prognosis. 4, 5 The activation of platelets and their subsequent aggregation have a pivotal role in the propagation of arterial thrombosis and therefore platelets are the key therapeutic targets in the management of ACS. 4, 5 Current guidelines place particular emphasis on dual antiplatelet therapy (DAPT) consisting of aspirin plus one of the P2Y12 receptor inhibitors, clopidogrel, prasugrel or ticagrelor, with the aim to reduce the risk of both acute ischaemic complications and recurrent atherothrombotic events.
Overall, a substantial reduction in mortality and morbidity of ACS patients has been achieved through the introduction of new antithrombotic drugs, along with improved intervention techniques and optimisation of patient handling to achieve short symptom-to-intervention times, followed by prolonged long-term management of patients. 6, 7 The multiple facets of current management in daily practice can only be assessed by means of large-scale registries, which explains why such studies have flourished in the last decade.
There is no universal definition of a registry. The Agency for Healthcare Research and Quality (AHRQ), one of 12 agencies within the U.S. Department of Health and Human Services, describes a registry broadly as "an organised system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes". , the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) 10 and others.
Real-world evidence (RWE) is a very important source of information on the efficacy and safety of clinical interventions. RWE has, however, major intrinsic limitations when analyzing clinical outcomes in relation to therapeutic management. In particular, potential unrecognized bias, even in the most clinically detailed registries, precludes drawing causal inferences between any given treatment and clinical outcomes. This has led the editors of the Heart Group Journals to publish a specific statement on the importance of matching language to the type of evidence gathered from observational studies compared with randomized clinical trials. 11 As an illustrative example, the definitive statement "intervention reduced risk" (an active verb)
should be reserved for randomised controlled trials (RCTs), while observational studies should use phrases such as, "lower risk was observed" or "there was a relationship with lower risk".
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Notwithstanding this caveat, registries, surveys and epidemiological studies have gained great importance in cardiology (as in other fields) as numerous examples show. 12, 13 In contrast to
RCTs, which enrol highly selected populations, registries usually recruit consecutive "all-comer patients" irrespective of concomitant diseases or co-medications. These patient groups are thus higher in medical complexity and risk. Sometimes differences are observed between outcome data from clinical trials and published RWE data. Event rates are likely to be higher in RWE settings due to the selective non-inclusion of the sickest patients in RCTs. Comparison between outcomes of controlled trials and observational trials allows researchers to check whether RCT findings in selected populations can be transferred to "real-world" patients (both in terms of baseline clinical characteristics and outcomes of treatment). 14 The "Platelet inhibition Registry in ACS EvalUation Study" (PIREAUS) group is a European initiative of experts in cardiology who are managing national or international ACS registries.
About twenty completed or ongoing registries have been set up in Europe to document clinical experience with ACS patients, many of whom undergo PCI and/or are treated with antiplatelet agents such as P2Y12-inhibitors. Individually, these registries are often too small to provide powerful datasets. The PIRAEUS working group therefore set out to integrate the wide array of data generated by individual European ACS registries to derive a complete picture of various aspects of the management of this condition.
The present overview introduces the participating registries in narrative and tabular form, and sets the basis for the upcoming publications that will focus on effectiveness (deaths and cardiac events) and safety (in particular, bleeding related to anticoagulation).
METHODS
The project was initiated during a meeting of pivotal members of the PIRAEUS group, who all are owners of or principal investigators in large ACS registries. They defined the criteria for including appropriate registries as: European multicentre or single-centre observational studies on real-life experience in the management of ACS; large unselected patient cohorts;
percutaneous coronary intervention as main revascularisation strategy; data on management during initial hospitalisation for ACS available; follow-up data on outcomes (death, cardiac events, bleedings) available.
Registries had to meet three further conditions: (1) the inclusion of patients from European countries, and (2) within the last 5 years, previous publication of data in peer-reviewed journals and/or reporting of unpublished data, with information on outcomes of drug treatment of patients with P2Y12 inhibitors at least until discharge from the hospital; (3) willingness of registry owners to take part in PIRAEUS and share data. A total of 17 registries that fulfilled all of the criteria were identified (overview in Table 1 ).
Data on the registries were extracted in two steps: a large table shell was developed in cooperation with the various registry holders. First, based on recent publications and congress presentations, data on study setting, methodology, patient characteristics, medical treatment and outcomes in terms of effectiveness and safety were collected by independent reviewers with expertise in the field. In the second step, the table was sent to the individual registry holders with the request to double-check data, enter corrections, and, if indicated, add unpublished (more current) data.
DESCRIPTION OF THE ACS REGISTRIES APCI and ADAPT (Austria)
The .
ATACS (Germany)
The ATACS (Antithrombotic Therapy in patients with Acute Coronary Syndrome) registry is a The data from the AMIS Plus registry are used to characterise patients with AMI and UA, record the examination and treatment strategies, assess compliance with guidelines, guide the optimisation of interventions, observe of changes over time as well as the economic consequences of treatment and the possible alternatives. 25 So far, the registry collected blinded data from more than 49,000 patients.
A pivotal paper on details and methods as well as on overview about the progress of AMIS Plus after 13 years' conduct has been published. 25 Further, more than 50 national and international catheter lab access. Patients with unstable angina were excluded from the study.
Overall, 5854 patients with STEMI and 5852 patients with NSTEMI were consecutively enrolled.
Data collection included pharmacological and non-pharmacological indicators of performance as well as measure of excess dose of antithrombotic drugs in eligible populations. Outcome measures during the in-hospital stay, at 30 days 37 and at 6 months 38 were also collected.
CPU Registry (Germany)
The German Chest Pain Unit (CPU) registry is a prospective multicentre registry in all parts of Germany. CPUs are an integral part of emergency cardiology services with the purpose to deliver quick and targeted identification of the origin of acute unclear chest pain. The German Cardiac Society (DGK) defined obligatory minimal standards for CPUs, which include 24-hour catheterization and intervention facilities. As all certified CPUs serve as gate to a catheterization lab, referral to a CPU are a fast-track to coronary angiography and intervention if required.
The German CP registry was set up in 2008 to internally and externally validate the medical care quality in the area of CPUs, including benchmark reports for general performance and risk-adjusted comparisons between centres. All types of hospitals, if certified as described, take part in this (ongoing) CPU registry.
Patients admitted to a CPU in Germany prospectively and consecutively. All forms of ACS are documented as a part of this patient group. Data are collected during the hospital stay, and in addition, during telephone interview at 3 months after the event. Data are not audited or monitored.
In a prospectively defined subgroup of patients with ACS, a 12-month follow-up was performed. This subgroup included 453 patients initially treated with prasugrel and a matchedpair group of 453 patients treated with clopidogrel. 
CZECH-2 (Czech Republic)
CZECH-2 is a prospective multicentre, observational, regional registry study in the Czech
Republic. It aims to provide epidemiologic data (incidence) on ACS as well as treatment and outcome data.
A total of 28 regional hospitals without catheterization availability and 4 cardiocentres with a catheterization laboratory (thus, all hospitals being parts of well-established PCI networks) in 4 counties in the South, North and West of the Czech Republic participated during the 2-month enrolment period between 1 October and 30 November 2012). This setup enabled to enrol all consecutive patients admitted during a given period to any existing hospital within a territory with well-defined population.
Patients were eligible for enrolment if they had an admission diagnosis of STEMI, NSTEMI, UA, acute heart failure with known coronary artery disease, chest pain with suspected ACS, resuscitation in the prehospital phase, or another initial diagnosis confirmed as ACS during hospitalization.
A report on the incidence of suspected versus confirmed ACS (including incidence of STEMI, Patients were eligible for documentation if they were admitted for suspected ACS (STEMI, NSTEMI, unclassified ACS, or unstable angina) that was first managed at the participating site (except prehospital treatment or admission a few hours after primary PCI at another site).
Informed consent was mandatory, but not required to analyse cases of in-hospital death.
Patients were excluded if ACS was secondary to other processes, such as tachyarrhythmia, severe anaemia, or surgery; if they had been transferred from another site where they had been admitted for ACS.
The characteristics of2557 ACS patients, their management and 6-month outcomes of the study have recently been published.
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EPICOR (international)
The "long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients" study (EPICOR) is a prospective, multinational, observational study. environments. 42 The study focuses on patients who survived the initial hospitalization for ACS;
thus, patients who died in hospital are not included in the study.
A methods/design paper reported the distribution of patients by countries and diagnoses (n=10,568 patients). 42 A number of subsequent papers reported international antithrombotic treatment patterns and opportunities for improvement of pre-and in-hospital care of ACS patients, 43 predictors of 1-year mortality at hospital discharge after ACS together with a new risk score 44 , contemporary inter-hospital transfer patterns 45 , as well as local analyses for example on the German centres 46 .
EYESHOT (Italy)
The "EmploYEd antithrombotic therapies in patients with acute coronary Syndromes Patients were eligible for documentation if they had STEMI or NSTEMI, which were defined by established electrocardiographic and laboratory criteria.
The treatment patterns in 2585 ACS patients by AMI type, and independent predictors for the novel P2Y12 inhibitors (prasugrel/ticagrelor) prescription in association with aspirin at discharge from hospital were presented in a recent publication. 47 In addition, a dedicated paper on antithrombotic therapies employed in ACS patients not receiving revascularization during the index admission 48 and on the impact of use of risk score on guidelines adherence 49 have been recently published.
FAST-MI (France)
The Patients were eligible for documentation if they had an acute myocardial infarction (STEMI and NSTEMI, but not unstable angina or iatrogenic AMI) and were admitted alive to the coronary care unit or intensive care unit within 48 hours of symptom onset. Patients who died very soon after admission and for whom cardiac markers were not measured were included if they had compatible signs or symptoms associated with typical ECG changes. Likewise, patients dying very early, before they could give informed consent, were included in the database unless the next of kin objected. incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction 60 , effect of coronary thrombus aspiration during primary PCI on 1-year survival, and 5-year survival according to modalities of reperfusion therapy.
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MINAP (England/Wales/Northern Ireland)
The Myocardial Ischaemia National Audit Project (MINAP) is a national cohort study (registry) set up in 2000 which contains data from patients with an ACS admitted to all (230) National Health Service (NHS) hospital trusts in England and Wales, and more recently those in Northern Ireland. 61 The registry aims at complete coverage of all ACS patients, regardless of where the patient is admitted within a hospital, though case ascertainment is incomplete. More than 40 publications have appeared from the registry, most recently mortality and missed opportunities along the pathway of care for STEMI a as national cohort study 62 , on the association between older age and receipt of care and outcomes in patients with ACS 63 , or age-dependent inequalities in improvements in mortality occur early after ACS 64 . Additionally the registry has been used to inform national policy and local quality improvement initiatives.
A report on hospital performance is made public each year 65 and limited information appears on government web pages. Hospital specific mortality outcome data (for STEMI) appeared for the first time in the public report 2013/14.
MULTIPRAC (international)
The It is an expert study, as centres were selected for participation if they performed at least 100
primary PCIs per year, were part of an admission network, and had a clearly defined prehospital treatment practice with thienopyridines in place. Patients were eligible if they had a STEMI diagnosis, and received upstream (pre-hospital) prasugrel or clopidogrel loading dose (LD, i.e. 300/600 mg for clopidogrel or 60 mg for prasugrel) immediately after the diagnosis and prior to/during ambulance transport to a cathlab hospital for primary PCI.
The study focuses on the use patterns and effectiveness of dual antiplatelet therapy (DAPT) initiated in the pre-hospital phase and mainly offers comparative data on DAPT based on prasugrel or clopidogrel. A total of 2053 STEMI patients were included and followed up for 1 year.
As of today, two major publications have emerged from this study, which describe the mortality and safety outcomes during the initial hospitalisation period, 66 and mortality after the one-year follow-up period, respectively (paper submitted).
SCAAR (Sweden)
The SCAAR (Swedish Coronary Angiography and Angioplasty Registry) is a prospective multicentre registry, with audit and monitoring procedures. Since 1990, it documents all consecutive coronary angiographies and PCI procedures performed in Sweden. 67 The registry covers all regions of Sweden and all 29 hospitals with a catheterization laboratory and enrols all patients.
Patients are eligible for inclusion, if they have an indication for angiography owing to stable coronary artery disease, acute coronary syndrome (unstable angina, NSTEMI and STEMI) or other indications (e.g. cardiac arrest, heart failure, arrhythmias).
The SCAAR registry is part of the SWEDEHEART registry collaboration which includes other databases like RIKS-HIA (the national Swedish cardiac intensive care registry), SEPHIA (followup after acute coronary syndromes), the national cardiothoracic surgery registry and the national TAVI registry. Data from these other registries can be merged with SCAAR in order to add additional information. Data from the Swedish National Population Registry is linked with SCAAR using personal identification numbers as permitted by the local laws to enable regular online updates on mortality in all patients.
Data from SCAAR are reported annually. 68 In addition, over 20 publications have described results, e.g. on treatment patterns and outcomes in patients undergoing PCI treated with prasugrel or clopidogrel in 2010-2011 69 , current treatment and outcome of coronary in-stent restenosis 70 , population trends in PCI over 2 decades 71 , or experience with various types of stents or balloons [72] [73] [74] [75] .
SPUM ACS (Switzerland)
The prospectively by an independent event adjudication committee. 77 As part of the SPUM ACS subproject, the ELIPS programme (Multi-dimEnsionaL prevention
Program after Acute coronary Syndrome) aims at improving quality of care and adherence to guidelines of patients admitted to hospital with Acute Coronary Syndrome (ACS) (https://clinicaltrials.gov/ct2/show/NCT01075867). This program reported reasons for nonprescription of recommended medications in ACS 78 and showed that discontinuation of recommended therapies after ACS differed per class of medication. 79 Moreover, this subproject investigated how application of the new 2013 AHA/ACC guidelines would change the proportion of patients achieving recommended lipid targets 1 year after ACS.
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A multimodality intracoronary imaging project assessed the effects of long-term high-intensity statin therapy on plaque burden, composition, and phenotype in non-infarct-related arteries of STEMI patients undergoing PCI.
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UK STEMI Newcastle
The Newcastle STEMI dataset is not a typical registry, but a retrospective analysis of prospectively collected data of the Freeman Hospital, Newcastle-upon-Tyne, in United
Kingdom. This is a regional tertiary centre serving a population of approximately 2 million and performing over 850 primary PCI cases per year. A single report has been issued to date on a total of 1668 patients not older than 75 years and over 60 kg in weight, who underwent primary PCI for STEMI between March 2008 and June 2011, comparing characteristics and 1-year mortality of consecutive patients.
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SUMMARY AND DISCUSSION
Observational studies including the ACS registries described in this overview are valuable in that they provide information about the course of disease, patient characteristics, patterns and changes in treatment approaches (in line with or deviating from guidelines), and outcomes in individuals managed under real-life conditions.
Only aggregated data are used in the PIRAEUS project, since no individual patient information could be exchanged between studies owing to data protection standards. While it is tempting to combine all data into one large database for extensive statistical analysis, the group members acknowledge that this strategy is accompanied by many challenges. One important caveat is that data have been collected for different purposes and in different ways. Thus, it must be carefully considered which data may and which may not be combined. In certain cases, the data from some registries may be compiled for analysis, but only when deemed appropriate.
Overall, the PIRAEUS working group concluded that addressing the same clinical question in separate analyses of data obtained with different methodologies may provide a better idea than analysis of huge numbers, but with many caveats.
Another important consideration is whether adjusted or unadjusted data should be presented.
The PIRAEUS working group reached consensus that it is often inappropriate to provide unadjusted data, as the registry data are inevitably the result of confounding by indication. For instance, a large difference in age and risk profile is commonly seen between patients treated with clopidogrel and prasugrel. If in specific situations, adjusting is possible and meaningful, data will be presented as such in the upcoming review papers.
We present similarities, but also, as expected, substantial differences in many aspects of the constitutes an important attribute for a study to achieve representativeness of the documented cohort and to avoid selection bias. 12, 14 Almost all registries included both STEMI and NSTEMI ACS patients, with the exception of MULTIPRAC and the Belgian registry, which focused on STEMI only. All registries provide data on mortality at least for the in-hospital phase, and a subset of 8 registries allows analyses by P2Y12 inhibitor treatment given for ACS.
About half of the registries were funded by industry (with unrestricted grants or assuming the sponsor role). Therefore, when interpreting the outcomes of registries, a number of methodological considerations apply to this study class. Different sources of bias and confounding can obscure any true causal association. 83 Clinical decisions of the treating physicians may assign patients to different drugs based on disease severity, disease duration, presence of comorbidities, and other factors. This can potentially introduce allocation or channelling bias and confound the association between treatment and outcomes. Selection processes with regard to centres (participants with higher levels of expertise) and patients (participants probably more adherent to therapy) may limit the transferability of findings to the overall healthcare system.
A major strength of those registries that are maintained long-term, such as AMIS-plus, MINAP and the ALKK registry, lies in the continuity of data collection, which allows analyses of changes over time. As guideline recommendations may not be durable owing to constantly improving medical knowledge 84 , registries open the unique opportunity to assess the timely implementation of necessary changes in medical or interventional treatments. 25 The various ACS registries presented in this overview have provided detailed insights on the management and outcomes of ACS patients. These registries will, both as individual projects and also in the context of PIRAEUS, contribute to the further improvement of treatment for these patients. 
